BioIntelliSense, Inc. news
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Med
Clinicians at Ardent’s BSA Hospital in Amarillo, Texas, began using the BioButton wearable device and BioCloud analytics engine in September to automate the collection of inpatient vital signs in general care units and increase both patient and clinician satisfaction. With plans for expansion across Ardent’s 30 hospitals, the program also leverages BioIntelliSense’s FDA-cleared AlertWatch, clinical intelligence and triage solution. The integrated dashboard and highly intuiti
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and a patented intuitive display of contextual patient data for more efficient, actionable clinical decisions. As part of the recently announced strategic partnership with Medtronic, its Patient Monitoring business will distribute Alert
- Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion
- Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced the launch of its patented, FDA-clear